|国家预印本平台
首页|复方浙贝颗粒治疗难治性急性白血病中医证候疗效观察

复方浙贝颗粒治疗难治性急性白血病中医证候疗效观察

randitional Chinese Symptom Efficacy of Fritillaria Thunbergii Bulb Complex Granules(FTBCG) of Refractory acute leukemia(RAL)

中文摘要英文摘要

目的:通过复方浙贝颗粒配合化疗治疗难治性急性白血病(RAL)中医证候改善的疗效观察,从中医角度进一步探讨复方浙贝颗粒治疗 RAL 的作用机理。方法:以“复方浙贝颗粒”为治疗药物,以 RAL 患者为研究对象,使用标准化疗方案的同时,于化疗开始前 3 天加用盲态下的治疗组或对照组颗粒剂,每次 1 袋,每 日 3 次,连续服药 14 天,以标准化疗疗程为一个治疗周期,根据“临床证候分级记分标准”内容记录患者的中医证候评分。结果:①证候评分显示,治疗组与对照组两组有效病例分别为63.6%与10.0%;无效病例分别为36.6%与90.0%,治疗组证候改善优于对照组。结论:围化疗期伍用复方浙贝颗粒治疗难治性急性白血病可改善患者的中医证候,提高患者生活质量。

o investigate the effect of the combination use of FTBCG with routine chemotherapeutics and seek why it can be effective from the view of the traditional Chinese medicine..METHODS: We adopted double-blind technique, many centre and random sampling for contrast. Separated 21 refractory acute leukemia patients into two teams, the therapy group(11cases,Fritillaria Thunbergii Bulb Complex Granules.po based on standard chemotherapeutics)and the control group(10cases,base on standard chemotherapeutics) .All cases were request to take their drug in 3 days before chemotherapy begins(10g t.i.d.) and take medicine for 14 days continuously. In this period,they don’t use any medicine which can reverses leukemia MDR..RESULTS: The score of the tranditional Chinese symptom show that in treatment group the effective cases are 63.6% ,the unavailing cases are36.6%. In the control group the effective cases are 10.0%, the unavailing cases are 90.0%. Comparing the total effective rate, there is statistical difference, P<0.05, the treatment group is better than the control group obviously.CONCLUSION: It was found that Fritillaria Thunbergii Bulb Complex Granules(FTBCG) of Refractory acute leukemia(RAL) could decrease the score of the tranditional Chinese symptom, and improve the patients’living standard.

陈信义、马薇、李冬云、姜静雯

中医学临床医学肿瘤学

难治性急性白血病中医证候复方浙贝颗粒

Fritillaria Thunbergii Bulb Complex Granules(FTBCG)Refractory acute leukemiathe tranditional Chinese symptom

陈信义,马薇,李冬云,姜静雯.复方浙贝颗粒治疗难治性急性白血病中医证候疗效观察[EB/OL].(2010-01-20)[2025-08-11].http://www.paper.edu.cn/releasepaper/content/201001-864.点此复制

评论